Received Jul 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | OT |
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | OT |
FBE calling to report an AE on behalf on an HCP in which the HCP did not want to provide any identifying information and does not want to be contacted regarding the case. HCP stated a patient received CAPVAXIVE in April 2025 and stated that his body; "fatigued and run down more than normal; This spontaneous report was received from a healthcare professional and refers to a male patient of unknown age near 70 years old. The patient's medical history, concurrent conditions and concomitant therapies were not reported. In 2021, the patient was vaccinated with Pneumococcal Vaccine, Polyvalent (23-valent) (PNEUMOVAX 23), administered by Unknown route (lot # and expiration date were not reported). On an unknown date, the patient experienced a reaction. In Apr-2025, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) administered by Intramuscular route (lot # and expiration date were not reported). Both vaccines were administered for Prophylaxis. After Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) vaccination, the patient stated that his body felt like it had a "stronger reaction than in previous vaccinations and that he felt fatigued and run down more than normal since 2025. The outcome of the events was unknown. No causality assessment was provided.